LEI NIE to United States Food and Drug Administration
This is a "connection" page, showing publications LEI NIE has written about United States Food and Drug Administration.
Connection Strength
0.206
-
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015 Mar 01; 21(5):950-4.
Score: 0.109
-
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and S?zary Syndrome. Clin Cancer Res. 2019 12 15; 25(24):7275-7280.
Score: 0.037
-
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018 08; 23(8):943-947.
Score: 0.034
-
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res. 2014 Aug 01; 20(15):3902-7.
Score: 0.026